PROFILPELAJAR.COM

Forever Labs

Forever Labs
Founded2015; 11 years ago (2015) in Ann Arbor, Michigan
Servicescryopreservation of bone marrow
Websiteforeverlabs.com

Forever Labs is a longevity company that uses an outpatient procedure to harvest adult Mesenchymal stem cells for possible future medical treatment. While the collection and storage of infant cord blood has become commonplace since the 1990s, Forever Labs is notable for being the first company to offer collection and storage of adult stem cells.[1]

History

Forever Labs was founded in Ann Arbor, Michigan in 2015 by Dr. Mark Katakowski, Dr. Ben Buller, Dr. Laith Farjo, and Steven Clausnitzer. After initial launch in Michigan, the company now operates in eight states. In the summer of 2017, Forever Labs was invited to participate in the Silicon Valley Incubator Y Combinator.[2]

Procedure

Forever Labs contracts with licensed physicians to perform the collection procedure. The patient lies on his/her side, the area just above the hip is disinfected and locally anesthetized. The physician then uses a special syringe to collect the bone marrow. The cells are spun down with special centrifuge devices, cooled and shipped off to the long term storage facility. The entire process typically takes 15–20 minutes.

Storage and future use

The patient's stem cells are stored in a clinical-grade cryogenic biorepository for future withdrawal, expansion, and use in disease prevention, longevity treatments, and regenerative medical treatments.

Hundreds of clinical trials[3] are currently underway studying the effects of stem cell therapy.

References

  1. ^ Buhr, Sarah. "Forever Labs preserves young stem cells to prevent your older self from aging". TechCrunch. Retrieved 2018-03-06.
  2. ^ Constine, Josh. "The top 7 startups from Y Combinator S'17 Demo Day 1". TechCrunch. Archived from the original on 2017-09-01. Retrieved 2017-09-01.
  3. ^ Steinberg, Gary K.; Kondziolka, Douglas; Wechsler, Lawrence R.; Lunsford, L. Dade; Coburn, Maria L.; Billigen, Julia B.; Kim, Anthony S.; Johnson, Jeremiah N.; Bates, Damien (2016-01-01). "Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study". Stroke. 47 (7): 1817–1824. doi:10.1161/STROKEAHA.116.012995. ISSN 0039-2499. PMC 5828512. PMID 27256670.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.